IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

29 Apr 2024 09:39:00 By Nasdaq GlobeNewswire

Immix Biopharma on Track to Dose NXC-201 Patients in United States

18 Apr 2024 09:32:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 Apr 2024 09:36:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

20 Mar 2024 09:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

05 Mar 2024 09:35:00 By Nasdaq GlobeNewswire

Immix Biopharma 12 Month Review Progress Update

21 Feb 2024 09:31:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

08 Feb 2024 16:45:00 By Nasdaq GlobeNewswire

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

07 Feb 2024 09:37:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

05 Feb 2024 22:30:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Proposed Public Offering of Common Stock

05 Feb 2024 15:20:11 By Nasdaq GlobeNewswire

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

24 Jan 2024 08:35:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

04 Jan 2024 09:34:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

18 Dec 2023 09:39:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

11 Dec 2023 09:36:00 By Nasdaq GlobeNewswire

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

30 Nov 2023 09:46:00 By Nasdaq GlobeNewswire

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

22 Nov 2023 09:19:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 Nov 2023 09:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 Nov 2023 09:46:00 By Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

06 Nov 2023 09:12:00 By Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

06 Nov 2023 08:40:00 By Nasdaq GlobeNewswire